Following intravenous administration vecuronium is rapidly distributed. It is taken up by the liver and partly metabolised; the metabolites have some neuromuscular blocking activity. It is excreted mainly in bile as unchanged drug and metabolites; some is also excreted in urine. The plasma elimination half-life is reported to range from about 30 to 80 minutes.
Adjunct to general anaeshtesia to facilitate endeotracheal intubation & to provede skeletal muscle relaxation
Dosage: Has to be individualised Intubation: 0.8mg/kg. Surgical procedures after intubation with succinylcholine: 0.03 to 0.05mg/ kg body wt. Use of vecuronium should be delayed till the patient has clinically recovered from the neuromuscular block induced by succinylcholine
Maintenance dose: 0.02 to 0.03 mg per kg.
Incompatibility with alkaline solutio(barbiturates such as thipentone sodium).
Inhalational anaesthetics: halothane, isoflurance amy enhance effect.
Antiarrhythmic: Lignocaine, quinidine and verapamil may enhanced effect.
Antibacterial: Aminoglycoside, lincosamide, polymixins & rarely tetracyclines may enhace effect.
Anticholinestrases: Neostigmine may enhance effect.
Antiepileptics: Carbamazepine and phenytoin may reduce effect.
Ganglion blockers: May enhance effect.
Xanthines: Aminophylline and theophlline may antagonise the effect.
Effect & Precaution
Transient fall in blood pressure, slight increase in heart rate, reduction in GI motility, rarely bronchospasm and anaphylactoid reaction.
Precaution: Hepatic and renal impairment. Dose adjustment may be required in infants. Severe obesity. Malignant hyperthermia.
Pregnancy: Safety not established.
Breast Feeding: Use only if clearly indicated.
Man: Use with caution.